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Background: We propose that single-nucleotide polymorphisms 
(SNPs) in genes of the vascular endothelial growth factor pathway 
of angiogenesis will associate with survival in non–small-cell lung 
cancer (NSCLC) patients.
Methods: Fifty-three SNPs in vascular endothelial growth factor-
pathway genes were genotyped in 150 European stage I–III NSCLC 
patients and tested for associations with patient survival. Replication 
was performed in an independent cohort of 142 European stage I–III 
patients. Reporter gene assays were used to assess the effects of 
SNPs on transcriptional activity.
Results: In the initial cohort, five SNPs associated (q < 0.05) with 
relapse-free survival (RFS). The minor alleles of intronic FLT1 SNPs, 
rs7996030 and rs9582036, associated with reduced RFS (hazard 
ratio [HR] = 1.67 [95% confidence interval, CI, 1.22–2.29] and HR = 
1.51 [95% CI, 1.14–2.01], respectively) and reduced transcriptional 
activity. The minor alleles of intronic KRAS SNPs, rs12813551 and 
rs10505980, associated with increased RFS (HR = 0.64 [0.46–0.87] 
and HR = 0.64 [0.47–0.87], respectively), and the minor allelic vari-
ant of rs12813551 also reduced transcriptional activity. Lastly, the 
minor allele of the intronic KRAS SNP rs10842513 associated with 
reduced RFS (HR = 1.65 [95% CI, 1.16–2.37]). Analysis of the func-
tional variants suggests they are located in transcriptional enhancer 
elements. The negative effect of rs9582036 on RFS was confirmed 
in the replication cohort (HR = 1.69 [0.99–2.89], p = 0.028), and the 
association was significant in pooled analysis of both cohorts (HR = 
1.67 [1.21–2.30], p = 0.0001).
Conclusions: The functional FLT1 variant rs9582036 is a prognostic 
determinant of recurrence in stage I–III NSCLC. Its predictive value 
should be tested in the adjuvant setting of stage I–III NSCLC.
Key Words: Non–small cell lung cancer, SNPs, VEGF pathway, 
FLT1, Enhancer.
(J Thorac Oncol. 2015;10: 1067–1075)
Disease stage appears to be the most important prognostic factor in non–small-cell lung cancer (NSCLC) patients, 
but disease recurrence is common even for patients with stage 
I–III disease.1 Molecular biomarkers that identify patients 
who will develop recurrence and might benefit from adjuvant 
therapy are sorely needed.2 Currently, there are no prognostic 
molecular markers or expression signatures in clinical use in 
resectable NSCLC.2
The angiogenic potential of many cancers, including 
NSCLC, impacts their clinical course. Angiogenesis is an 
essential event in tumor growth, progression, and metastasis 
formation and is regulated by several angiogenic cytokines, 
mainly those of the vascular endothelial growth factor (VEGF) 
pathway.3–5 In NSCLC, tumor vascularization and levels of 
VEGF pathway proteins have been found to be associated with 
patient outcomes.6 Trials testing bevacizumab in the adjuvant 
setting have been negative, and an ongoing randomized study 
(Eastern Cooperative Oncology Group 1505) might provide the 
definitive answer to the role of adjuvant bevacizumab.
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As angiogenesis is a host-mediated process, germline 
genetic variation in the VEGF pathway is likely to affect the angio-
genic potential of a tumor.7,8 A small number of single-nucleotide 
polymorphisms (SNPs) in VEGF pathway genes have been tested 
for association with outcomes in NSCLC and other solid tumors 
(reviewed by Eng et al.,9 Lambrechts et al.,10 and Schneider 
et al.11), but there is little information about the functional signifi-
cance of germline variation in genes of the VEGF pathway. Thus, 
there is no mechanistic basis to support many of these associa-
tions, in part explaining the inconsistent results from these stud-
ies.11 Without prospective validation of findings already built in at 
the time of the initial discovery, the demonstration of the clinical 
validity of biomarkers is a lengthy and difficult process.
The aim of this study was to identify germline variants in 
the VEGF pathway genes that associate with NSCLC survival 
and may act as markers of angiogenic-dependent tumor recur-
rence. NSCLC patients were genotyped for candidate VEGF 
pathway SNPs to test associations with patient survival. To aid 
the interpretation of these associations, the molecular function 
of SNPs was characterized by examining their effects on tran-
scriptional activity in reporter gene assays. Finally, the SNPs 
found to associate with survival were also prospectively tested 
in a validation cohort of European stage I–III NSCLC patients 
to provide an independent assessment of our findings.
METHODS
Ethics Statement
Tissue banking and related research was approved 
by institutional review boards at the Medical University 
of Gdansk, Poland and the General University Hospital of 
Valencia, Spain. All patients signed an informed consent.
Initial Patient Cohort
The initial cohort consisted of 150 White European stage 
I–III NSCLC patients who underwent pulmonary resection. 
They belonged to a cohort of unselected patients systemati-
cally diagnosed with resectable NSCLC with tumor samples 
collected at the Medical University of Gdansk, Poland. Median 
follow-up of the study group was 63.4 (range, 13.1–82.3) 
months. Relapse-free survival (RFS) was defined from the 
date of surgery to the date of local or distant relapse, death of 
any cause, or last follow-up. Overall survival (OS) was defined 
from the date of surgery to the date of death of any cause or 
last follow-up. Relapse of disease was assessed by chest radio-
grams or computed tomography scans every 3 months for the 
first 2 years and every 6–12 months thereafter. The patient 
characteristics are described in Table 1. Adjuvant therapy was 
given to only 4.6% of patients.12 Postoperative chemotherapy 
was not routinely administered in the analyzed period per 
institutional guidelines. Primary tumors were fresh frozen at 
the time of surgery. All patients signed an informed consent. 
Further details of the cohort were described previously.12
SNP Selection and Genotyping 
in the Initial Cohort
In the initial patient cohort, 53 SNPs (minor allele 
frequency > 5%) in 13 candidate genes (identified from the 
PharmGKB VEGF signaling pathway web resource: www.
pharmgkb.org/pathway/PA2032#tabview=tab1&subtab=) 
were selected using several approaches: SNPs associated 
with mRNA expression in lymphoblastoid cell lines; SNPs 
identified from our prior study13; SNPs in HIF1A and FLT1 
(not expressed in lymphoblastoid cell lines) predicted to be 
functional by FastSNP and FuncPred; nonsynonymous SNPs 
predicted to change protein structure according to FastSNP; 
and SNPs identified from previous association studies. 
Detailed information on the SNPs according to these criteria 
is provided (see Supplementary Table, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A827, which identifies 
VEGF pathway gene SNPs genotyped in the initial cohort).
Genomic DNA prepared from fresh frozen patient tumor 
samples (AllPrep DNA/RNA kit, Qiagen, Germantown, MD) 
was used for genotyping. Five KDR SNPs had been genotyped 
as described previously.14 The remaining SNPs were genotyped 
by TaqMan (Applied Biosystems, Foster City, CA) per the man-
ufacturer’s instructions using a CFX384 Real-Time System 
(Bio-Rad, Hercules, CA), and Sanger-based DNA sequenc-
ing (Mammalian Genotyping Core at the University of North 
Carolina at Chapel Hill) was used to validate representative 
samples and determine thresholds for allelic discrimination. 
SNP allele frequencies were comparable with those previously 
reported from the HapMap and 1000 Genomes projects (see 
Supplementary Table, Supplemental Digital Content 1, http://
links.lww.com/JTO/A827, which identifies VEGF pathway 
gene SNPs genotyped in the initial cohort). For rs9582036 
in FLT1 and rs10505980 in KRAS, additional quality control 
of the genotyping was performed using the genotype calls in 
the tumor DNA and matching germline DNA in squamous 
NSCLCs from The Cancer Genome Atlas (see Supplementary 
Table, Supplemental Digital Content 2, http://links.lww.com/
JTO/A828, which illustrates FLT1 rs9582036 and KRAS 
rs10505980 genotype calls from squamous NSCLC genotyped 
samples from The Cancer Genome Atlas). Linkage disequi-
librium (LD) was analyzed using the SHEsis application. No 
SNPs deviated from Hardy–Weinberg equilibrium after con-
trolling for multiple testing using a false discovery rate (FDR) 
at q < 0.05 (see Supplementary Table, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A827, which identifies 
VEGF pathway gene SNPs genotyped in the initial cohort).
Reporter Gene Assays
To support the interpretation of the associations between 
SNPs and survival, we analyzed the molecular effects of five 
SNPs, which passed a FDR threshold (q < 0.05) for associa-
tion with RFS in the initial cohort. Luciferase reporter assays 
can test the transcriptional effects of genetic variants in poten-
tial regulatory genetic regions. When the functional effects 
of SNPs are unknown (as for the five SNPs associated with 
RFS in this study), these assays are critical to provide the 
mechanistic basis of the clinical associations.15 The pGL4.26 
(Promega, Madison, WI) plasmid with minimal promoter and 
Firefly luciferase gene was used, and the cloning approach is 
described in Supplementary Methods (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A829). Three DNA 
clones of each reporter gene construct were prepared for 
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transfection into murine endothelial (SVEC4-10, kind gift 
from Mark Lingen at the University of Chicago) and human 
embryonic kidney (HEK-293) cells. Cell culture conditions are 
described in Supplementary Methods (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A829). Cells were trans-
fected using lipofectamine 2000 (Invitrogen, Carlsbad, CA), 
the reporter gene construct of interest and Renilla TK plas-
mid (Promega, Madison, WI). Each construct was transfected 
in three independent experiments, using triplicate wells. The 
Dual-Luciferase Reporter Assay kit (Promega, Madison, WI) 
was used to measure luciferase activity as per the manufactur-
er’s instructions. Luciferase activity was defined as a ratio of 
Firefly to Renilla luciferase and was normalized to the lucif-
erase activity of the wild-type construct in each experiment.
Validation Patient Cohort
We tested prospectively whether any of the five SNPs 
passing the FDR for association with RFS in the initial cohort 
(Table 2) would associate with RFS in an independent, exter-
nal validation cohort. Hence, these five SNPs were genotyped 
in DNA extracted from fresh frozen tumor samples of 142 
White European stage I–III NSCLC patients from Spain.16 
A CONSORT chart is provided (see Supplementary Fig., 
Supplemental Digital Content 4, http://links.lww.com/JTO/
A830, which shows the CONSORT chart). Clinical and 
demographic variables of the patients are provided in Table 1. 
Patients were systematically diagnosed with operable, his-
tologically confirmed NSCLC at the General University 
Hospital of Valencia, Spain. Median follow-up of the study 
group was 37.3 months (95% confidence interval [CI], 29.3–
43.5). Recurrence of disease was assessed by chest computed 
tomography scan every 3 months for the first 2 years and 
every 6–12 months thereafter, using the same criteria of the 
initial cohort. Further details of the cohort were described 
previously.16
SNP Genotyping Methods in 
the Validation Cohort
Patient tumor specimens were obtained at the time of 
the surgery and preserved in RNAlater (Applied Biosystems, 
Carlsbad, CA) at −80°C until the analysis. Nucleic acid isola-
tion and genotyping using TaqMan SNP assays are described 
in Supplementary Methods (Supplemental Digital Content 3, 
http://links.lww.com/JTO/A829).
Statistical Analyses
Survival was estimated according to the Kaplan–Meier 
method. Patient characteristics were tested for association 
with survival using a Mantel–Cox log-rank test to identify 
potential prognostic factors. The genetic associations with 
survival in each cohort were then adjusted for these factors, 
and the independence of the genetic associations was tested 
using additive Cox proportional hazards models. Because we 
propose that functional VEGF pathway SNPs impact tumor 
angiogenesis and growth, we have chosen RFS as the primary 
TABLE 1.  Initial and Validation Cohorts: Patient Characteristics, Relapse-Free Survival (RFS) and Overall Survival (OS) (Log-Rank 
Test)
Initial Cohort Validation Cohort
n (%)
Median OS 
Months  
(95% CI) P Value
Median RFS 
Months  
(95% CI) P Value n (%)
Median OS 
Months  
(95% CI) P Value
Median RFS 
Months  
(95% CI) P Value
Sex 0.08 0.14 0.26 0.26
  Female 37 (25) 62 (15.4–NR) 49 (13.7–NR) 20 (14) NR (NR–NR) NR (NR–NR)
  Male 113 (75) 23 (17.5–39.8) 18 (13.1–25.7) 122 (86) 67 (30.9–NR) 44.3 (26.2–NR)
Disease stage <0.0001 <0.0001 0.64 0.30
  I 64 (43) NR (48.6–NR) 62 (36.9–NR) 78 (55) NR (32.3–NR) 48.3 (43.5–NR)
  II 33 (22) 37 (20.3–NR) 22 (16.8–NR) 35 (25) 42.9 (29.8–NR) 26.2 (16.3–NR)
  III 53 (35) 10 (7.8–13.3) 8 (6.0–11.0) 29 (20) NR (17.2–NR) NR (11.2–NR)
Histology 0.31 0.42 0.03 0.04
  Squamous 88 (59) 25 (16.2–41.6) 17 (11.6–36.9) 67 (47) NR (42.6–NR) 48.3 (26.2–NR)
  Adenocarcinoma 42 (28) 61 (20.9–NR) 36 (17.7–NR) 55 (39) 67 (42.9–NR) NR (37.9–NR)
  Othersa 20 (13) 15 (9.1–NR) 15 (7.2–NR) 20 (14) 17.1 (12.9–NR) 11.2 (7.3–NR)
Ever smokers 0.96 0.69 0.40 0.61
  No 7 (5) 21 (7.16–NR) 18 (3.4–NR) 19 (13) NR (NR–NR) NR (17.9–NR)
  Yes 143 (95) 28 (17.8–48.6) 21(13.5–36.9) 123 (87) 67 (32.3–NR) 45.8 (29.2–NR)
Age (years) 0.13 0.33 0.30 0.30
  <65 78 (52) 36 (21.3–NR) 22 (13.7–62.4) 74 (52) NR (42.6–NR) NR (43.5–NR)
  >65 72 (48) 21 (12.6–48.6) 18 (8.4–38.6) 68 (48) 53.3 (27.9–NR) 31.9 (21.1–NR)
  Median (range) 64 (37–85) 64 (26–82)
In the validation cohort, adjuvant therapy was administered to 56 patients and was not associated with either RFS or OS (results not shown).
aInitial cohort = not otherwise specified, Validation cohort = 6 large cell carcinoma, 4 adenocarcinoma-squamous cell carcinoma, 2 carcinoid, 8 not otherwise specified.
NR, not reached; CI, confidence interval.
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end point as it relates to tumor growth or the appearance 
of new lesions17 and, compared with OS, is less likely to be 
affected by events (including treatment) occurring after recur-
rence. In the initial cohort, FDR was applied to correct for 
multiple testing (a q < 0.05 was considered significant), geno-
types were coded additively, and associations were adjusted 
for stage, the only variable associated with RFS in this cohort 
(Table 1). In the validation cohort, identical statistical methods 
to those of the initial cohort were used; however, a one-sided 
test was used because we hypothesized that we would observe 
the same directionality of association in the validation cohort. 
Moreover, because the mode of heritance for these SNPs in 
the initial cohort was always dominant, a dominant model 
was used to test the associations in the validation cohort and 
the associations were adjusted for histology, the only variable 
associated with RFS in this cohort (Table 1). In the combined 
cohort test, a one-sided test and a dominant model were used, 
and the associations were not adjusted.
Differences in reporter assays were analyzed by Student’s 
t test or analysis of variance followed by Dunnett’s multiple 
comparisons test in GraphPad Prism (GraphPad Software, 
Inc, La Jolla, CA) (p < 0.05 for significance). All other statis-
tical analyses were carried out using the R Statistical environ-
ment along with extension packages.
RESULTS
Five SNPs Associate with RFS in 
the Initial NSCLC Cohort
Of the 53 SNPs genotyped in 150 European stage I–III 
NSCLC patients, 5 SNPs (two in FLT1 and three in KRAS) 
associated with RFS and passed the FDR threshold for signifi-
cance (q < 0.05, Table 2). Disease stage was incorporated into 
these models because it significantly associated with RFS and 
OS (p < 0.0001, Table 1).
The minor alleles of the intronic FLT1 SNPs rs7996030 and 
rs9582036 associated with reduced RFS (hazard ratio [HR] = 1.67 
[95% CI, 1.22–2.29] and HR = 1.51 [95% CI, 1.14–2.01], 
respectively); for rs7996030 in a dominant model, the 
median RFS of patients with GA + AA genotypes was 2.1-
fold shorter than that of GG patients (HR = 2.13 [1.38–3.28], 
p = 0.0006, Fig. 1A); and for rs9582036 in a dominant model 
(in modest LD with rs79906030, r2 = 0.44), the median RFS 
of patients with CA + CC genotypes was 2.9-fold shorter than 
that of AA patients (HR = 1.77 [1.18–2.67], p = 0.006, Fig. 1B).
The minor alleles of the intronic KRAS SNPs rs12813551 
and rs10505980 associated with increased RFS (HR = 0.64 
[0.46–0.87] and HR = 0.64 [0.47–0.87], respectively); for 
rs12813551 in a dominant model, the median RFS of patients 
with TC + CC genotypes was 4.3-fold longer than that of 
TT patients (HR = 0.49 [0.32–0.74], p = 0.0008, Fig. 1C); 
and for rs10505980 in a dominant model (in high LD with 
rs12813551, r2 = 0.83), the median RFS of patients with GA 
+ AA genotypes was 3.7-fold longer than that of GG patients 
(HR = 0.49 [0.33–0.75], p = 0.0008).
The minor allele of the intronic KRAS SNP rs10842513 
was associated with reduced RFS (HR = 1.65 [1.16–2.37]), 
and in a dominant model, the median RFS of patients with 
CT + TT genotypes was 3.8-fold shorter than that of CC patients 
(HR = 1.97 [1.22–3.18], p = 0.006, Fig. 1D). An additional 
seven SNPs nominally associated with RFS (p < 0.05) but did 
not pass the FDR threshold (Table 3).
As a secondary analysis, associations with OS were 
similarly tested. Nine SNPs nominally associated with OS 
(p < 0.05, see Supplementary Table, Supplemental Digital 
Content 5, http://links.lww.com/JTO/A830, which identifies 
initial cohort nominal associations of SNPs with OS [p < 0.05] 
in Cox regression models adjusted for stage), but none passed 
the FDR threshold. However, all five SNPs passing FDR for 
RFS (Table 2) had an effect on OS concordant with that on 
RFS (p < 0.02 for these SNPs).
Three SNPs Demonstrate Functional 
Effects on Reporter Gene Expression
To provide a mechanistic explanation for the genetic 
associations with RFS, SNPs were assessed for regulatory 
activity using luciferase reporter gene assays. Genomic 
regions containing the SNPs were cloned downstream of 
the luciferase gene in a construct containing a minimal pro-
moter, and assays were performed to determine the effects 
of the SNPs on the transcriptional activity of the minimal 
promoter. An intronic region containing the minor allele of 
the FLT1 SNP rs9582036 or rs7996030 (associated with 
reduced RFS) reduced transcriptional activity in an endo-
thelial cell line (SVEC) by 33% (p < 0.0001) and 23% 
(p < 0.0001), respectively, when compared with a reference 
TABLE 2.  Initial and Validation Cohorts: Associations of SNPs With Relapse-Free Survival (RFS) (Cox Regression)
SNP Alleles Gene
Initial Cohort Validation Cohort
HR 95% CI P value Q value HR 95% CI P value
rs7996030 G>A FLT1 1.67 1.22–2.29 0.0014 0.0490 1.37 0.78–2.42 0.1382
rs9582036 A>C FLT1 1.51 1.14–2.01 0.0044 0.0490 1.69 0.99–2.89 0.0275
rs10505980 G>A KRAS 0.64 0.47–0.87 0.0049 0.0490 1.17 0.68–2.01 0.2890
rs12813551 T>C KRAS 0.64 0.46–0.87 0.0052 0.0490 0.91 0.53–1.58 0.3698
rs10842513 C>T KRAS 1.65 1.16–2.37 0.0060 0.0490 1.09 0.49–2.44 0.4136
In the initial cohort, data are adjusted for stage and pass the false discovery rate correction (q < 0.05) for multiple testing in additive genetic models. In the validation cohort, data are 
adjusted for histology, associations are for dominant genetic models (because all five associations in the initial cohort had a dominant model), and the p values are for a one-sided test, as 
the associations were tested prospectively on the basis of the results obtained from the initial cohort. SNPs are ranked by p value of SNP-RFS associations observed in the initial cohort.
SNP, single-nucleotide polymorphism; HR, hazard ratio; CI, confidence interval.
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FIGURE. 1.  Kaplan–Meier plots of significant single-nucleotide polymorphism (SNP)-relapse-free survival (RFS) asso-
ciations after false discovery rate (FDR) correction (q < 0.05) in initial cohort. Symbols denote censored points. A, 
rs7996030: median RFS is 11.1 (95% CI, 5.8–25.7) and 23.5 (17.7–NR) months for patients with GA + AA and GG 
genotypes. B, rs9582036: median RFS is 13.1 (7.2–20.7) and 38.3 (21.1–NR) months for patients with CC + AC and 
AA genotypes, respectively. C, rs12813551: this plot is also representative of rs10505980 because of the high Linkage 
disequilibrium (LD) with rs12813551. Median RFS is 39.2 (21.8–NR) and 9.1 (7.0–16.8) for patients with CC + TC and 
TT genotypes, respectively. D, rs10842513: median RFS is 6.6 (4.6–22.2) and 25.1 (17.1–49.9) months for patients with 
CC + TC and TT genotypes, respectively. Although these results are for associations adjusted for stage, the plots are for 
unadjusted data.
TABLE 3.  Initial Cohort: Nominal Associations of SNPs with Relapse-Free Survival (RFS, p < 0.05) in Cox Regression Models 
Adjusted for Stage
SNP Alleles Gene HR 95% CI P value Q Value
rs4246229 A>G KRAS 0.71 0.54–0.94 0.0168 0.1120
rs34176876 A>- KRAS 0.72 0.55–0.95 0.0191 0.1120
rs1570360 G>A VEGFA 1.39 1.03–1.87 0.0290 0.1428
rs1951795 C>A HIF1A 1.47 1.03–2.11 0.0341 0.1428
rs11549465 C>T HIF1A 1.62 1.02–2.57 0.0392 0.1428
rs542403 A>G FRS2 0.66 0.44–0.98 0.0404 0.1428
rs2076139 C>T MAPK11 0.70 0.49–0.99 0.0417 0.1428
SNPs are ranked by significance of SNP-RFS associations.
The associations with p greater than 0.05 are available upon request.
SNP, single-nucleotide polymorphism; HR, hazard ratio; CI, confidence interval.
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construct containing the major allelic variants (Fig. 2A). 
The effect on transcriptional activity was even more pro-
nounced when both minor alleles were tested in the same 
construct: activity was reduced up to 45% (p < 0.0001; 
Fig. 2A). Neither SNP had a significant effect on transcrip-
tional activity in HEK-293 cells (Fig. 2B), suggesting that 
the effects of the variants may be cell-type or tissue-type 
specific, as is characteristic of transcriptional enhancers. 
Moreover, analysis of ENCODE functional genomic data 
indicated that the FLT1 region examined contains a puta-
tive enhancer element, coincident with rs7996030 and pos-
sibly extending to rs9582036 (see Supplementary Fig. A, 
Supplemental Digital Content 6, http://links.lww.com/JTO/
A832, which illustrates evidence of putative transcriptional 
enhancer elements at FLT1 loci).
For the KRAS SNPs rs12813551 and rs10505980, an 
intronic region containing the minor alleles of both variants 
(associated with increased RFS) reduced transcriptional activ-
ity in SVEC cells by 18% (p = 0.014; Fig. 2C). Neither SNP had 
a significant effect by itself in SVEC cells, though the minor 
allele of rs12813551 reduced transcriptional activity by 15% 
(p = 0.051). In HEK-293 cells, the minor allele of rs12813551 
reduced transcriptional activity by 19% (p < 0.001), but neither 
the minor allele of rs10505980 nor the construct containing 
the minor alleles of both SNPs had a significant effect (Fig. 
2D). Analysis of ENCODE data suggests that rs12813551 
is coincident with a putative transcriptional enhancer, while 
rs10505980 is approximately 1.5 kb downstream of this ele-
ment (see Supplementary Fig. B, Supplemental Digital Content 
6, http://links.lww.com/JTO/A832, which illustrates evidence 
of putative transcriptional enhancer elements at KRAS loci).
An intronic region containing the minor allele of the 
KRAS SNP rs10842513 (associated with reduced RFS) dem-
onstrated no effect in SVEC cells (Fig. 2E) and only a mar-
ginal increase (9%, p = 0.054) in transcriptional activity in 
HEK-293 cells (Fig. 2F). ENCODE data did not provide evi-
dence for substantive transcriptional enhancer activity at this 
SNP locus (see Supplementary Fig. C, Supplemental Digital 
Content 6, http://links.lww.com/JTO/A832, which illustrates 
lack of evidence of putative transcriptional enhancer elements 
at KRAS rs10842513 locus).
FIGURE 2. FLT1 and KRAS single-nucleotide polymorphisms (SNPs) affect transcriptional activity in reporter gene assays. 
Relative luciferase activity of FLT1 SNPs in SVEC (A) and HEK-293 (B) cell lines and KRAS SNPs in SVEC (C, E) and HEK-293 (D, 
F) cell lines. Values were normalized to those of the reference sequences containing the major allelic variants of the SNPs of 
interest. Significance was tested by Student’s t test or analysis of variance followed by Dunnett’s multiple comparisons test in 
GraphPad Prism (for significance: *p < 0.05; ***p < 0.001; ****p < 0.0001).
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The Association of rs9582036 and RFS 
Replicates in Validation Cohort
We prospectively tested whether any of the five SNPs 
passing the FDR for the association with RFS in the initial 
cohort (Table 2) associated with RFS in an independent, exter-
nal validation cohort of 142 European stage I–III NSCLC 
patients (Table 1).16 Of the 5 SNPs, only rs9582036 in FLT1 
had a significant and concordant effect (Table 2): the RFS of 
patients with the AC + CC genotypes was shorter than that 
of AA patients (HR = 1.57 [0.93–2.66], p = 0.045, Fig. 3A). 
When this association was adjusted for histology (the only 
parameter associated with RFS, Table 1), the HR was 1.69 
[0.99–2.89], p = 0.028. The adjustment for stage (as in the ini-
tial cohort) did not improve this association (HR = 1.57 [95% 
CI, 0.92–2.66], p = 0.049).
In a pooled analysis of both cohorts (n = 292), the HR 
of rs9582036 for RFS (adjusted for stage, using a dominant 
model) was 1.67 (95% CI, 1.21–2.30), with a marked separa-
tion between the two survival curves (p = 0.0001, Fig. 3B); 
without adjusting for stage, the HR was 1.81 [1.32–2.49], 
p = 0.0001).
DISCUSSION
The VEGF pathway genetic studies of NSCLC outcome 
have focused so far on a small number of genes and genetic 
variants, in particular VEGFA.9 We rationally selected 53 
SNPs from 13 VEGF pathway genes and identified 5 SNPs in 
FLT1 and KRAS that associated with RFS after correction for 
multiple testing. We subsequently validated the association of 
the FLT1 SNP rs9582036 with RFS in an independent cohort 
of stage I–III European NSCLC patients. Molecular studies of 
germline SNPs associated with patient outcome are essential 
to guide the assessment of their clinical utility,15 and we found 
functional evidence to support the clinical associations of the 
two FLT1 SNPs (rs7996030 and rs9582036) and one of the 
KRAS SNPs (rs12813551). Furthermore, all three functional 
variants were found to be located in or adjacent to putative 
transcriptional enhancer elements. The finding that the FLT1 
SNPs had an additive effect on gene expression is consistent 
with a recent proposal that multiple enhancer variants coop-
eratively act to modestly alter gene expression and account for 
genetic associations with disease.18
The most important result of this study is that the vari-
ant allele (C) of the FLT1 SNP rs9582036 is associated with 
shorter RFS in both the initial and the validation cohorts 
(Table 2, Figs. 1 and 3). rs9582036 is a common germline 
variant (frequency of approximately 30% in Caucasians), 
and this association is supported by the finding that this 
variant is functional. A putative transcriptional enhancer 
element is located immediately adjacent to rs9582036 and 
possibly extends into the locus of this SNP in lung tissue 
(see Supplemental Digital Content 6A, http://links.lww.com/
JTO/A832, which illustrates evidence of putative transcrip-
tional enhancer elements at FLT1 loci). The minor allele of 
rs9582036 reduces transcriptional activity and thus suggests 
that this variant may act through this element to reduce FLT1 
expression. Intriguingly, the effect of rs9582036 was only 
observed in the SVEC cell line, indicating that the effect 
may be specific to endothelial cells and that this variant may 
have effects on angiogenesis in vivo.
There is evidence to suggest that the clinical association 
and the molecular effect of rs9582036 reconcile with the biol-
ogy of FLT1. FLT1 encodes the VEGF receptor 1 (VEGFR-1), 
a mediator of tumor endothelial function.19 Its level of 
phosphorylation in response to VEGFA is low,20,21 and its 
soluble form is expressed by endothelial tumor cells, seques-
tering VEGFA through the formation of a complex.22 Soluble 
VEGFR-1 also inhibits VEGFA in a dominant manner by 
heterodimerizing with the ligand binding region of VEGFR-
2,23 the most potent receptor of VEGFA, which mediates 
most of the proangiogenic effects of VEGFA. Enhanced in 
vivo expression of soluble VEGFR-1 by tumor cells inhibits 
solid tumor growth, impedes metastatic nodule development, 
and extends host survival.19 In addition to its soluble form, 
upregulation of membrane-anchored VEGFR-1 in endothelial 
cells contributes to the readjustment of the tumor endothelial 
phenotype in response to increased oxygen supply and vessel 
FIGURE 3.  Kaplan–Meier plots 
of the association between the 
rs9582036 single-nucleotide 
polymorphism (SNP) in FLT1 
and relapse-free survival (RFS) in 
the validation cohort (A) and in 
the combined initial and valida-
tion cohorts (B). Symbols denote 
censored points. The plots are for 
unadjusted data.
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normalization.24 These lines of evidence are strongly sugges-
tive of FLT1 being a negative regulator of neovasculariza-
tion (see review by Olsson et al.19). Hence, collectively, these 
findings fit a mechanistic model where reduced endothelial 
expression of VEGFR-1, mediated by rs9582036, could accel-
erate NSCLC recurrence through increased angiogenesis.
On the basis of the results of this study, we hypothesize 
that carriers of the minor allele of the rs9582036 FLT1 vari-
ant may be less responsive to angiogenesis inhibition, as a 
result of a potentiated angiogenic tumor phenotype. Indeed, 
rs9582036 is predictive of shorter survival in bevacizumab-
treated patients with metastatic pancreatic and renal cell car-
cinoma.25 The negative predictive effect is also observed in 
other nonrandomized studies of anti-VEGF therapies: beva-
cizumab (colorectal26) and sunitinib (renal cell27). Because 
results from different tumor types might not be necessarily 
extended to the setting of stage I–III NSCLC, more molecular 
and cellular studies in ex vivo angiogenesis models are needed 
to dissect the resulting effect of FLT1 genetic variation on 
both the basal NSCLC endothelial phenotypes and response 
to VEGF blockade.
A major question is whether there is now sufficient evi-
dence to regard rs9582036 as a validated prognostic marker of 
recurrence in stage I–III NSCLC. RFS was the primary end 
point in our study, and for a genetic association that relates to 
the biology of the tumor, RFS should be robust to confound-
ers that could not be accounted for. We acknowledge that the 
demonstration of a prognostic role of rs9582036 in FLT1 for 
cancer-related OS is probably warranted before this novel 
marker could be used to inform treatment decisions in stage 
I–III NSCLC patients. In this setting, interventions after recur-
rence should be taken into account to avoid the confounding 
related to imbalances in active therapies. The lack of recom-
mendations on the use of adjuvant chemotherapy in higher 
risk NSCLC after surgery in the cancer institute treating study 
patients may also represent a limitation of the present study.
Our study did not replicate the effect of three KRAS 
SNPs on RFS (Table 2). These findings may have been false 
positives, or the effects of the SNPs could have been con-
founded by hidden heterogeneity between the two cohorts. 
The patients in the validation cohort were not enrolled to 
match the characteristics of the initial cohort; therefore, intrin-
sic patient differences across the two cohorts might hamper 
the detection of true positive associations. Furthermore, only 
rs12813551 demonstrated functionality, and its effects were 
modest in the reporter gene assays. It may be that these SNPs 
are in LD with the causal variants underlying the clinical asso-
ciations, and thus, fine mapping studies may help clarify these 
associations. Nonetheless, the KRAS SNP rs12813551 should 
still be tested in other studies as its molecular effect is consis-
tent with the clinical association and the oncogenic biology of 
KRAS in NSCLC. Moreover, a negative prognostic impact of 
increased KRAS expression in operable NSCLC has been pre-
viously demonstrated,28 and the minor allele of rs12813551, 
associated with increased RFS, had a negative effect on tran-
scriptional activity.
In summary, we identified several associations between 
VEGF pathway SNPs and NSCLC outcome and provided 
biological interpretations through molecular studies. A 
prospective validation study has selected rs9582036 in FLT1 
as a germline variant associated with poor prognosis in stage 
I–III NSCLC. These results provide the foundation for testing 
the prognostic and predictive value of functional VEGF path-
way SNPs in NSCLC patients administered chemotherapy and 
anti-VEGF therapies.
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